One ‘Must-Buy’ Dividend Stock To Weather Market Volatility

Geopolitical tensions may offer some clarity for where investors should put their money…

Since the start of 2022, U.S. indexes have been extremely volatile, as the S&P 500, Dow Jones, Nasdaq Composite, and Russell 2000 have all see-sawed over the past two months. 

Driving this has been Wall Street’s focus on the Russia-Ukraine crisis… as well as the Federal Reserve’s potential rate hikes. 

So far, the central bank has noted that it needs to end its easy-money policies to combat inflation. As a result, Goldman Sachs (GS) believes the Fed will increase interest rates at least seven times in 2022. 

Meanwhile, Russia has invaded Ukraine. This not only tanked the country’s own economy and stock market, but also drove declines in European markets… while sending oil prices to dangerously high levels as well. 

This has stoked fears in Wall Street and global money managers. However, it has also offered some clarity as to where investors should place their money to protect their portfolios. 

In turn, many institutional investors are shifting over to more defensive plays – including dividend-yielding stocks such as AbbVie (ABBV). 

AbbVie is an American-based pharmaceutical company, which was originally spun off from Abbott Laboratories in 2013.

It has quickly become a highly-profitable firm that owns the best-selling drug in the world, Humira. Humira is an antibody-based inflammation treatment for diseases such as rheumatoid arthritis. 

And even though its patent will run out in 2023, the company has taken significant steps to maintain its dominant market position.

Over the past three years, AbbVie has made a series of strategic investments to diversify its portfolio. In 2020, it finalized its $63 billion purchase of Botox maker Allergan, giving it more than 180 “aesthetic-focused” products. 

Meanwhile, AbbVie has also invested in its oncology, virology, and neuroscience divisions. This has resulted in a variety of treatments for cancer, brain-related issues, and other diseases. 

This has clearly paid off for the pharmaceutical firm as well. In its fourth-quarter report, AbbVie said its earnings per share were $3.31 compared with the projected $3.28. And its revenue was in line with estimates at $14.89 billion. 

And these efforts will likely continue to boost the company as it builds out its businesses moving forward. So, these factors, AbbVie’s consistent revenue stream, and its dividend yield of 3.9% should benefit shareholders through current market volatility.

Is Amazon Obligated to Pay You?

Sponsored

This shocking news could make you $48,000 richer…

After 24 years of steady growth, Amazon has been accused of being anticompetitive.

And it's been quietly slapped with a “tax” that's worth more than $938.2 million every single year.

Now, thanks to U.S. law, you can claim your slice of this jackpot and collect up to $48,000 over the next year.

All you'll need to do is follow the steps in this presentation.

I urge you to act quickly.

The next payout will happen on March 14. You won't want to miss this.

Get the full details here.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works